C
Takeda Pharmaceutical Company Limited TAK
$15.19 $0.211.40%
Recommendation
Hold
Prev Close
$14.98
Volume
4,306,754
Avg Vol (90D)
1,730,341
Market Cap
$45.67B
Dividend & Yield
$0.5056(3.38%)
52-Week Range
$12.58 - $15.31
P/E (TTM)
17.52
EPS (TTM)
$0.8548
My Lists My Alerts
Rating
Reward
C
Fair
Risk
C-
Fair
Rating Factors
Growth Index
Weak
Efficiency Index
Good
Solvency Index
Good
Total Return Index
Weak
Volatility Index
Fair
Dividend Index
--
Headlines
European, Asian pharma stocks rally as Trump spares sector from reciprocal tariffs but the cheer may be shortlived
4/3/2025 - Invezz News
Raymond James Financial Inc. Invests $1.45 Million in Takeda Pharmaceutical Company Limited (NYSE:TAK)
4/3/2025 - MarketBeat
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
3/31/2025 - Zacks Investment Research
Takeda Pharmaceutical Co. Ltd. Buys Shares of 203,190 Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)
3/28/2025 - MarketBeat
Takeda Pharmaceutical Co. Ltd. Acquires Shares of 823,317 Lyell Immunopharma, Inc. (NASDAQ:LYEL)
3/28/2025 - MarketBeat
77,733 Shares in American Well Co. (NYSE:AMWL) Purchased by Takeda Pharmaceutical Co. Ltd.
3/28/2025 - MarketBeat
Takeda Pharmaceutical Co. Ltd. Makes New Investment in Shattuck Labs, Inc. (NASDAQ:STTK)
3/28/2025 - MarketBeat
Takeda Pharmaceutical Co. Ltd. Takes Position in HilleVax, Inc. (NASDAQ:HLVX)
3/28/2025 - MarketBeat
Charles Schwab Investment Management Inc. Raises Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)
3/28/2025 - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) Announces Approval of LIVMARLI in Japan
3/27/2025 - GuruFocus
Takeda's HyQvia receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)
3/27/2025 - CNW Group - News Releases
Takeda Pharmaceutical (NYSE:TAK) Sets New 12-Month High - Time to Buy?
3/25/2025 - MarketBeat
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
3/24/2025 - Zacks Investment Research
Summit Global Investments Has $9.66 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)
3/23/2025 - MarketBeat
69,083 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Purchased by Boston Partners
3/23/2025 - Ticker Report
Natixis Advisors LLC Acquires 21,539 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)
3/23/2025 - MarketBeat
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
3/19/2025 - Zacks Investment Research
Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High - What's Next?
3/18/2025 - MarketBeat
Takeda Pharmaceutical Company Limited (NYSE:TAK) Position Lowered by Brandes Investment Partners LP
3/16/2025 - MarketBeat
TAK or DSNKY: Which Is the Better Value Stock Right Now?
3/14/2025 - Zacks Investment Research
Will ADMA Biologics Stock Continue Its Momentum in 2025?
3/14/2025 - Zacks Investment Research
Naviter Wealth LLC Has $228,000 Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)
3/10/2025 - MarketBeat
US Bancorp DE Has $1.65 Million Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)
3/9/2025 - MarketBeat
Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by Smartleaf Asset Management LLC
3/8/2025 - Ticker Report
Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - Time to Buy?
3/8/2025 - Ticker Report
Income Statement
Total Revenue (TTM)
$30.24B
EBITDA (TTM)
$7.69B
EBIT (TTM)
$3.24B
Net Income (TTM)
$1.37B
Balance Sheet
Total Assets (Q)
$96.09B
Total Debt (Q)
$34.55B
Total Liabilities (Q)
$48.90B
Book Value Per Share (Q)
$29.77
Cash Flow
Cash from Operations (TTM)
$7.38B
Cash from Investing (TTM)
-$2.68B
Cash from Financing (TTM)
-$3.40B
Net Change in Cash (TTM)
$1.34B
Filings
Filing Date
Thursday, January 30, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Jun 23 and 27 (est)
Price History
Loading...
Beta
0.17
7-Day Total Return
1.00%
30-Day Total Return
9.60%
60-Day Total Return
14.21%
90-Day Total Return
14.30%
Year to Date Total Return
14.64%
1-Year Total Return
14.37%
2-Year Total Return
-3.17%
3-Year Total Return
12.48%
5-Year Total Return
22.73%
52-week Low
Jun 20, 2024 - $12.58
52-week High
Mar 21, 2025 - $15.31
Valuation
Market Cap
$45.67B - Large Cap
Enterprise Value
$78.74B
Price/Sales (TTM)
0.79
Price/Book (Q)
0.50
Dividends and Shares
Shares Outstanding
1.59B
Dividend Per Share (Most Recent)
$0.2672
Dividend Per Share (TTM)
$0.5056
Corporate Info
Website
www.takeda.com
Phone Number
81 3 3278-2111
Address
1-1, Nihonbashi-Honcho 2-chome
Tokyo, 103-8668
Country
Japan
Year Founded
1781
Business Description
Sector
--
Industry
--
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers... more
NYSE 04/03/2025 4:00PM Eastern Quotes delayed
Weiss Ratings